IRIS
MUSOLINO, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.102
NA - Nord America 5.569
EU - Europa 3.184
SA - Sud America 970
AF - Africa 386
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 8
Totale 16.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.373
SG - Singapore 2.654
CN - Cina 1.193
VN - Vietnam 1.040
IE - Irlanda 838
BR - Brasile 745
HK - Hong Kong 545
IT - Italia 488
SE - Svezia 401
DE - Germania 368
ZA - Sudafrica 245
NL - Olanda 227
FR - Francia 226
IN - India 118
CA - Canada 112
FI - Finlandia 112
BD - Bangladesh 111
GB - Regno Unito 104
RU - Federazione Russa 84
AR - Argentina 81
UA - Ucraina 78
AT - Austria 72
IQ - Iraq 56
TR - Turchia 52
MX - Messico 41
EC - Ecuador 38
PH - Filippine 38
BE - Belgio 37
CI - Costa d'Avorio 37
PK - Pakistan 37
PL - Polonia 36
ES - Italia 32
ID - Indonesia 30
JP - Giappone 30
KR - Corea 28
VE - Venezuela 25
CO - Colombia 23
CL - Cile 22
MA - Marocco 22
MY - Malesia 20
TW - Taiwan 20
UZ - Uzbekistan 19
TH - Thailandia 18
A1 - Anonimo 16
SA - Arabia Saudita 16
TN - Tunisia 16
KE - Kenya 15
PY - Paraguay 15
CZ - Repubblica Ceca 12
EG - Egitto 11
LT - Lituania 11
AE - Emirati Arabi Uniti 10
UY - Uruguay 9
DZ - Algeria 8
IL - Israele 8
NI - Nicaragua 8
IR - Iran 7
JO - Giordania 7
AU - Australia 6
AZ - Azerbaigian 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HR - Croazia 6
NG - Nigeria 6
PE - Perù 6
HU - Ungheria 5
JM - Giamaica 5
OM - Oman 5
PS - Palestinian Territory 5
RO - Romania 5
SY - Repubblica araba siriana 5
AL - Albania 4
BG - Bulgaria 4
EU - Europa 4
HN - Honduras 4
NP - Nepal 4
PA - Panama 4
PT - Portogallo 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
CR - Costa Rica 3
GT - Guatemala 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
MU - Mauritius 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
GH - Ghana 2
GR - Grecia 2
IS - Islanda 2
KG - Kirghizistan 2
LV - Lettonia 2
Totale 16.208
Salva come PNG Salva come JPEG
Città #
Singapore 1.317
Dublin 822
Ashburn 777
Chandler 667
San Jose 641
Hong Kong 514
Beijing 457
Santa Clara 381
Ho Chi Minh City 309
Hanoi 230
Johannesburg 225
Boardman 219
Dallas 218
Lauterbourg 165
Princeton 147
New York 146
Ann Arbor 140
Shanghai 117
Los Angeles 115
Bremen 105
Des Moines 81
Helsinki 73
Parma 66
São Paulo 64
Seattle 63
Munich 62
Jacksonville 61
Vienna 60
Grafing 57
Moscow 55
Wilmington 55
Milan 52
Montreal 52
Da Nang 50
Haiphong 46
Hefei 43
Frankfurt am Main 39
Buffalo 38
Abidjan 37
Columbus 37
Dearborn 32
Nuremberg 31
Brussels 30
Bologna 27
Rio de Janeiro 27
Rome 26
Toronto 26
Nanjing 25
Tokyo 23
Baghdad 22
Brooklyn 22
San Mateo 22
Stockholm 22
The Dalles 20
Amsterdam 19
Phoenix 19
Shenyang 19
Warsaw 19
Belo Horizonte 18
Tashkent 18
Atlanta 17
Hải Dương 17
Jinan 17
London 17
Council Bluffs 15
Jakarta 15
Woodbridge 15
Biên Hòa 14
Boston 14
Brasília 14
Denver 14
Fairfield 14
Istanbul 14
Can Tho 13
Changsha 13
Chicago 13
Curitiba 13
Dhaka 13
Nairobi 13
Pune 13
Tianjin 13
Ardea 12
Fremont 12
Houston 12
Poplar 12
Rio Saliceto 12
Thái Bình 12
Campinas 11
Madrid 11
Orem 11
Salvador 11
Bangkok 10
Borås 10
Cape Town 10
Casablanca 10
Charlotte 10
Guayaquil 10
Karachi 10
Naples 10
San Francisco 10
Totale 9.777
Salva come PNG Salva come JPEG
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 292
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 167
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 158
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 157
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 154
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 153
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 153
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 152
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 150
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 149
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 148
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 147
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 146
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 146
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 145
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 144
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 143
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 141
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 141
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 140
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 139
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 139
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 135
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 135
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 134
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 133
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 133
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 132
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 131
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 127
A review of immune checkpoint blockade in breast cancer 124
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 123
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 123
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 122
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 121
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 121
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 119
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 118
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 118
p73 and p53 pathway in human breast cancers. 118
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 116
My best choice after a round trip from illness 116
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 115
A narrative review of the principal glucocorticoids employed in cancer 113
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 112
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 112
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 111
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 111
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 111
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 111
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 109
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 107
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 107
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 106
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 105
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 104
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 104
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 104
In reply 103
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 102
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 102
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 101
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 100
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 99
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 98
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 97
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 94
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 94
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 92
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 92
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 91
Role of Fcγ receptors in HER2-targeted breast cancer therapy 91
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 91
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 90
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 90
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 90
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 90
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 90
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 89
Breast Cancer in Italy: Stage and Region Distribution 89
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 88
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 88
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 87
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 87
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 86
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 86
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 86
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 85
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 85
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) 83
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 83
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 83
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 81
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 81
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 81
Indicators of cure for women living after uterine and ovarian cancers: a population-based study 79
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 78
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 77
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 77
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy 76
Totale 11.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.981
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202190 0 0 0 0 0 0 0 0 0 0 70 20
2021/2022622 23 11 24 28 16 67 32 42 41 26 26 286
2022/20232.680 328 196 134 177 260 255 18 183 952 23 122 32
2023/20241.097 53 112 16 32 97 225 106 117 40 79 64 156
2024/20253.531 70 209 285 171 394 315 91 114 476 383 293 730
2025/20267.372 660 754 906 589 988 347 944 211 1.037 683 253 0
Totale 16.495